Keyora Skin Systems Nutrition – Collagen Tripeptides EP-2: The Processing-to-Bioavailability Framework: From Enzymatic Peptide-Spectrum Engineering to Gly-Pro-Hyp Exposure and Skin-Relevant Biology

Collagen supplements may share a common protein origin while differing substantially in their molecular composition and subsequent human exposure. Native collagen, gelatin, conventional hydrolysates, and tripeptide-enriched preparations are not interchangeable analytical materials. Keyora Skin Systems Nutrition – Collagen Tripeptides EP-2 develops the Keyora Processing-to-Bioavailability Framework to explain how manufacturing-defined peptide composition becomes an experimentally identifiable nutritional input and how evidence must be separated across digestion, absorption, circulation, tissue distribution, and clinical skin outcomes. Chapter 1 distinguishes declared collagen mass from material state, processing history, molecular-weight distribution, and sequence-specific peptide identity. Chapter 2 examines protease specificity, hydrolysis conditions, fractionation, and analytical validation. Degree of hydrolysis, average molecular weight, total tripeptide fraction, and intact Gly-Pro-Hyp (GPH) content represent distinct measurements. The Analyte-Based Preparation Passport links batch identity and processing records with reproducible peptide-length and sequence profiles rather than assuming that smaller peptides or greater enrichment automatically confer superior bioavailability. Chapter 3 follows the post-ingestion pathway: gastric and pancreatic processing, brush-border transformation, short-peptide intestinal transport, bloodstream appearance, and experimentally investigated tissue utilization. PEPT1-associated uptake and GPH-to-Pro-Hyp transformation provide mechanistic context, while human studies establish time-dependent circulating GPH, Pro-Hyp, and Hyp-Gly after specified collagen preparations. Animal skin-distribution experiments and cultured human dermal fibroblast findings, including Pro-Hyp-related STAT3/HAS2 signaling and hyaluronic-acid synthesis, represent separate mechanistic evidence rather than demonstrated human dermal delivery or clinical efficacy. Chapter 4 introduces the Peptide Composition-to-Exposure Evidence Matrix. Iwai and Iwasaki demonstrated circulating hydroxyproline-containing peptides after gelatin-derived materials, whereas Yamamoto compared CTP-100, CTP-50, and a collagen-peptide comparator and identified preparation-related differences in plasma GPH and Pro-Hyp. The administered GPH quantities differed, preventing a simple claim of superior fractional absorption. Further studies by Yazaki, Taga, and Virgilio illustrate sequence-specific persistence and preparation-dependent exposure rather than universal rankings based on animal source or mean molecular weight. Chapter 5 applies the framework to Keyora’s tilapia-scale-derived ingredient: a 1,500 mg two-tablet serving, declared 30% tripeptide fraction, 459 Da average molecular weight, and more than 50% combined glycine, proline, and hydroxyproline composition. These declarations do not specify the intact GPH dose. Evidence from a separately studied tripeptide-containing preparation reporting selected skin hydration, elasticity, and wrinkle improvements cannot establish equivalent efficacy for the finished Keyora formula. The resulting framework is: Oral Ingestion → Gastrointestinal Digestion → Intestinal Absorption → Bloodstream Transport → Tissue Distribution → Biological Utilization, followed by separate Skin-Function Evidence. Its central conclusion is that reproducible peptide identity enables preparation-matched research, but systemic peptide detection, experimental tissue responses, and clinical skin benefit remain different evidence objects requiring independent validation.